A carregar...
Indolent lymphomas: pushing the pace with novel agents
Chemoimmunotherapy has been a hallmark of treatment of indolent B-cell non-Hodgkin lymphomas for the past 2 decades, with high response rates seen but relapses nearly inevitable and patients spending, on average, 20 years on and off treatment. Treatment advances, then, should be aimed at maintaining...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913469/ https://ncbi.nlm.nih.gov/pubmed/31808854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|